My guess is that Cramer knows as much about Amarin as most doctors know about Vascepa. Which is little. He's vaguely following 10,000 stocks. With scant knowledge about the ins and outs of most of them, he says wishy washy things that amount to "It might go up. It might go down." And that's exactly what he did today with Amarin.